Observational studyNeurourology and urodynamics2026
Impact of COVID-19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study.
Observational study in Neurourology and urodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID-19, and to assess associations with comorbidities, disease severity, and vaccination status.
methodsWe conducted a prospective cohort study of adult patients hospitalized with confirmed COVID-19, who were not in intensive care at the time of enrollment, between July 2021 and March 2022. LUTS were assessed using the International Prostate Symptom Score (IPSS), International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB), and ICIQ-Urinary Incontinence Short Form (ICIQ-UI SF) questionnaires during hospitalization and at one and 3 months post-discharge. Moderate to severe LUTS were defined as an IPSS > 7. Overactive bladder symptoms (OAB symptoms) were defined as an ICIQ-OAB Score ≥ 3 plus urgency and/or urgency urinary incontinence (UUI). Associations with sex, comorbidities, COVID-19 severity, and vaccination status were analyzed using multivariable logistic regression.
resultsAmong 168 patients (55.4% male, median age 58 years), 31.0% had moderate to severe LUTS during hospitalization, with storage symptoms predominating. Urgency was present in 21.4% of the cohort, and 36.7% met the criteria for OAB symptoms. Urinary incontinence (UI) affected 34.5%, being more frequent among women. At 3 months, moderate to severe LUTS declined to 21.9%, and both OAB symptoms and UI also decreased significantly. No associations were found between LUTS and comorbidities or disease severity. Fully vaccinated patients had higher odds of moderate to severe LUTS during hospitalization (adjusted OR 10.56, 95% CI 4.13-26.9), particularly those vaccinated with inactivated virus vaccines (BBIBP-CorV).
conclusionsLUTS are prevalent in the acute phase of COVID-19, especially among women, but tend to improve within 3 months. Unexpectedly, full vaccination-especially with inactivated virus vaccines-was associated with increased odds of moderate to severe LUTS during hospitalization. Further studies are warranted to explore the underlying mechanisms and long-term implications.
trial registrationThis study was not registered at ClinicalTrials.gov, as it is an observational study with no clinical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.